Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Targacept

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

Setback for GSK as melanoma vaccine misses targets

Cancer immunotherapy disappoints in phase III

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

- PMLiVE

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

- PMLiVE

Alzheimer’s disease pipeline takes multiple hits

Following a number of recent failures of clinical compounds, researchers are shifting the focus from late-stage disease to early-stage or prophylactic therapies

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

- PMLiVE

Vical’s cancer immunotherapy fails in late-stage trial

Allovectin no better than standard chemotherapy

- PMLiVE

Isis drops arthritis candidate

ISIS-CRP Rx disappoints in phase II

- PMLiVE

FDA fast-tracks Elan’s Alzheimer’s drug

Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

Roche - Basel

Late-stage blow to Roche’s diabetes ambitions

Halts development of aleglitazar on safety and efficacy concerns

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links